Bruker Q3 2026 Earnings: Margin Expansion Outpaces Modest Revenue Growth

Bruker (Nasdaq: BRKR) reported Q3 2026 revenue of $874.0 million, up 1.6% year over year, while GAAP diluted EPS was a loss of $0.81 versus a loss of $0.41 and non-GAAP diluted EPS increased 24.4% to $0.56. Organic revenue growth remained modest at 0.7%, but cost discipline helped lift non-GAAP operating margin by 400 basis points, while a $174.5 million non-cash goodwill impairment weighed on GAAP results.

Core Earnings Data

Acquisitions contributed 1.7 percentage points to revenue growth, while foreign-currency translation reduced growth by 0.8 percentage points. Revenue increased 2.4% at constant exchange rates, compared with organic growth of 0.7%.

Profitability diverged sharply between GAAP and adjusted results. GAAP gross margin expanded as cost of revenue declined, but the goodwill impairment pushed the company deeper into an operating loss. Excluding the impairment and other company-defined adjustments, operating income and EPS both increased.

Business and Segment Performance

Bruker Scientific Instruments, the company’s largest business group, generated $793.9 million of revenue, up 0.8% on a reported basis but down 0.4% organically. BEST provided the clearest growth contribution, with reported revenue up 11.2% and organic revenue up 11.8%.

Within BSI, BIOS and BMID posted modest increases, while Bruker Nano declined. Bruker reorganized its reportable segments effective July 1, 2026, and recast prior-period information to match the new structure.

Geographically, revenue increased to $231.2 million in the United States and $320.2 million in Europe. Asia-Pacific revenue declined by approximately 1.9% to $247.7 million, making it the only disclosed geographic category with a year-over-year decrease.

A $174.5 Million Impairment Widens the GAAP Loss as Adjusted Margins Expand

The largest factor separating GAAP and non-GAAP performance was the $174.5 million non-cash goodwill impairment. Total operating-level non-GAAP adjustments were $233.6 million, turning a $91.0 million GAAP operating loss into $142.6 million of non-GAAP operating income. Other adjustments included acquisition-related costs and amortization of purchased intangible assets.

The underlying cost structure also improved. Non-GAAP SG&A expense declined to $213.8 million from $227.1 million, while reported research and development expense decreased to $92.0 million from $98.3 million. Management attributed the adjusted margin expansion and EPS growth to cost discipline and execution.

The quarter therefore presents two different pictures: GAAP profitability deteriorated because of the impairment, while the company’s adjusted operating performance improved despite limited organic revenue growth.

FY2026 Guidance

Bruker reconfirmed its FY2026 organic revenue growth and non-GAAP EPS outlook. The principal update was currency: foreign exchange is now expected to have a neutral revenue impact, compared with the previous expectation for a 0.5% tailwind.

Organic revenue declined 0.3% during the first nine months of 2026, so achieving the full-year organic growth range requires a stronger fourth-quarter performance than the year-to-date trend.

Management Commentary

Management said BSI’s book-to-bill ratio remained above one for a fifth consecutive quarter. BSI organic bookings and backlog were both up by mid-single-digit percentages year to date, and the company reported strengthening demand across most end markets, including the U.S. academic market during Q3.

CEO Frank H. Laukien connected these order trends with expectations for faster revenue growth, continued margin expansion, and double-digit EPS growth in FY2027. These comments represent management’s outlook rather than formal quantitative FY2027 guidance.

Risks Investors Need to Monitor

• Organic growth remains limited: Q3 organic growth was 0.7%, while BSI organic revenue declined 0.4% and nine-month companywide organic revenue declined 0.3%. The FY2026 target therefore depends on improved fourth-quarter growth.
• GAAP and adjusted results remain far apart: The $174.5 million goodwill impairment was the largest adjustment, but acquisition costs and intangible amortization also contributed to the difference between the GAAP loss and adjusted profit.
• Currency support has weakened: The expected foreign-exchange contribution was reduced from a 0.5% revenue tailwind to neutral, leaving operating performance and acquisitions to carry more of the reported growth target.
• Performance is uneven across businesses and regions: BEST grew at a double-digit rate, while BSI organic revenue, Bruker Nano revenue, and Asia-Pacific revenue declined. A broader recovery would be needed to make growth less dependent on selected areas.

Summary

Bruker’s Q3 2026 results combined modest revenue and organic growth with a substantial improvement in adjusted profitability. BEST led segment growth, and lower expenses supported a 400-basis-point increase in non-GAAP operating margin, but the goodwill impairment widened the GAAP loss. The main issues to watch are whether stronger bookings convert into faster organic revenue growth, whether BSI and Asia-Pacific improve, and whether Bruker can deliver its reconfirmed FY2026 targets without the previously expected currency benefit.